An integrated mechanism of cardiomyocyte nuclear Ca2+ signaling

Cristián Ibarra, Jose Miguel Vicencio, Manuel Varas-Godoy, Enrique Jaimovich, Beverly A. Rothermel, Per Uhlén, Joseph A. Hill, Sergio Lavandero

Producción científicarevisión exhaustiva

14 Citas (Scopus)

Resumen

In cardiomyocytes, Ca2+ plays a central role in governing both contraction and signaling events that regulate gene expression. Current evidence indicates that discrimination between these two critical functions is achieved by segregating Ca2+ within subcellular microdomains: transcription is regulated by Ca2+ release within nuclear microdomains, and excitation-contraction coupling is regulated by cytosolic Ca2+. Accordingly, a variety of agonists that control cardiomyocyte gene expression, such as endothelin-1, angiotensin-II or insulin-like growth factor-1, share the feature of triggering nuclear Ca2+ signals. However, signaling pathways coupling surface receptor activation to nuclear Ca2+ release, and the phenotypic responses to such signals, differ between agonists. According to earlier hypotheses, the selective control of nuclear Ca2+ signals by activation of plasma membrane receptors relies on the strategic localization of inositol trisphosphate receptors at the nuclear envelope. There, they mediate Ca2+ release from perinuclear Ca2+ stores upon binding of inositol trisphosphate generated in the cytosol, which diffuses into the nucleus. More recently, identification of such receptors at nuclear membranes or perinuclear sarcolemmal invaginations has uncovered novel mechanisms whereby agonists control nuclear Ca2+ release. In this review, we discuss mechanisms for the selective control of nuclear Ca2+ signals with special focus on emerging models of agonist receptor activation.

Idioma originalEnglish
Páginas (desde-hasta)40-48
Número de páginas9
PublicaciónJournal of Molecular and Cellular Cardiology
Volumen75
DOI
EstadoPublished - oct. 1 2014

Financiación

This work was funded by Comision Nacional de Ciencia y Tecnologia (CONICYT), Chile: FONDECYT 1120212 to SL, Anillo ACT1111 to SL and EJ; FONDAP 15130011 to SL; Red Internacional CONICYT 120003 to JAH, BAR, and SL; by the NIH ( HL-120732 , to JAH; HL100401 , to JAH; HL-072016 , to BAR; HL-097768 , to BAR), AHA ( 0640084N , to JAH), AHA ( SDG18440002 , to JAH); CPRIT ( RP110486P3 , to JAH), and the Leducq Foundation ( 11CVD04 , to JAH).

FinanciadoresNúmero del financiador
Comision Nacional de Ciencia y Tecnologia
National Institutes of HealthHL-120732, HL-072016, HL100401
National Heart, Lung, and Blood InstituteR01HL097768
Cancer Prevention and Research Institute of TexasRP110486P3
Fondation Leducq11CVD04
Fondo Nacional de Desarrollo Científico y Tecnológico1120212, ACT1111
Animal Health AustraliaSDG18440002, 0640084N
Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias120003, 15130011

    ASJC Scopus Subject Areas

    • Molecular Biology
    • Cardiology and Cardiovascular Medicine

    Huella

    Profundice en los temas de investigación de 'An integrated mechanism of cardiomyocyte nuclear Ca2+ signaling'. En conjunto forman una huella única.

    Citar esto